Zum Hauptinhalt springen
Dekorationsartikel gehören nicht zum Leistungsumfang.
Biomarkers of Human Longevity
Taschenbuch von Dmitry Kaminskiy
Sprache: Englisch

87,25 €*

inkl. MwSt.

Versandkostenfrei per Post / DHL

Lieferzeit 1-2 Wochen

Kategorien:
Beschreibung
There is perhaps no other single technology or industry subsector, with the exception of AI, that has more potential to accelerate the realization of real-world impacts in Longevity across the full scope of its sectors and domains - industry, policy, investment, entrepreneurship, policy, and governance - than Biomarkers of Human Longevity.

Given the unique confluence of Biomarkers of Human Longevity's disruptive impact and accelerative potential, on the one hand, and the high degree of disharmonization in terms of what they are and how they could and should be used, on the other hand, it is clear to me that there is a pressing unmet need for the production of a dedicated book that takes Biomarkers of Longevity as its central concern and major fulcrum, identifying the true potential that this technology has to increase individual and national Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Expectancy (QALY), optimize strategic decision-making for start-ups and corporations, de-risk investment, provide for the first time a tangible framework for company valuation, due diligence based on human validation, enable reliable forecasting clinical outcomes, serve as an effective platform for safe self-experimentation and personalized therapeutic fine-tuning, and pave the way for a much more tangible, stable and scalable Global Longevity Industry, where Longevity's socially-inclusive humanitarian impact is maximized and its potential ethical and socioeconomic concerns are neutralized.

Deep Knowledge Group and its Longevity-focused subsidiaries and affiliates, including its analytical subsidiary Aging Analytics Agency, its specialized investment arm Longevity.Capital, its portfolio companies Longevity Banking Card and Longevity Financial Advisors and the international non-profit consortium Longevity.International, have prioritized the pressing need and the extreme potential of Biomarkers of Human Longevity (and integrated them in various ways into its overall scope of activities and strategic agenda) for several years now, and are expertly positioned to provide a tangible understanding of the major challenges and opportunities to be faced within this domain, and how they can be applied by individuals, institutions and even entire governments in order to achieve their maximum benefits while neutralizing potential pitfalls and issues.
There is perhaps no other single technology or industry subsector, with the exception of AI, that has more potential to accelerate the realization of real-world impacts in Longevity across the full scope of its sectors and domains - industry, policy, investment, entrepreneurship, policy, and governance - than Biomarkers of Human Longevity.

Given the unique confluence of Biomarkers of Human Longevity's disruptive impact and accelerative potential, on the one hand, and the high degree of disharmonization in terms of what they are and how they could and should be used, on the other hand, it is clear to me that there is a pressing unmet need for the production of a dedicated book that takes Biomarkers of Longevity as its central concern and major fulcrum, identifying the true potential that this technology has to increase individual and national Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Expectancy (QALY), optimize strategic decision-making for start-ups and corporations, de-risk investment, provide for the first time a tangible framework for company valuation, due diligence based on human validation, enable reliable forecasting clinical outcomes, serve as an effective platform for safe self-experimentation and personalized therapeutic fine-tuning, and pave the way for a much more tangible, stable and scalable Global Longevity Industry, where Longevity's socially-inclusive humanitarian impact is maximized and its potential ethical and socioeconomic concerns are neutralized.

Deep Knowledge Group and its Longevity-focused subsidiaries and affiliates, including its analytical subsidiary Aging Analytics Agency, its specialized investment arm Longevity.Capital, its portfolio companies Longevity Banking Card and Longevity Financial Advisors and the international non-profit consortium Longevity.International, have prioritized the pressing need and the extreme potential of Biomarkers of Human Longevity (and integrated them in various ways into its overall scope of activities and strategic agenda) for several years now, and are expertly positioned to provide a tangible understanding of the major challenges and opportunities to be faced within this domain, and how they can be applied by individuals, institutions and even entire governments in order to achieve their maximum benefits while neutralizing potential pitfalls and issues.
Details
Erscheinungsjahr: 2021
Fachbereich: Allgemeines
Genre: Wirtschaft
Rubrik: Recht & Wirtschaft
Medium: Taschenbuch
ISBN-13: 9781916391772
ISBN-10: 191639177X
Sprache: Englisch
Ausstattung / Beilage: Paperback
Einband: Kartoniert / Broschiert
Autor: Kaminskiy, Dmitry
Hersteller: Deep Knowledge Group
Maße: 234 x 156 x 26 mm
Von/Mit: Dmitry Kaminskiy
Erscheinungsdatum: 19.10.2021
Gewicht: 0,924 kg
Artikel-ID: 120804813
Details
Erscheinungsjahr: 2021
Fachbereich: Allgemeines
Genre: Wirtschaft
Rubrik: Recht & Wirtschaft
Medium: Taschenbuch
ISBN-13: 9781916391772
ISBN-10: 191639177X
Sprache: Englisch
Ausstattung / Beilage: Paperback
Einband: Kartoniert / Broschiert
Autor: Kaminskiy, Dmitry
Hersteller: Deep Knowledge Group
Maße: 234 x 156 x 26 mm
Von/Mit: Dmitry Kaminskiy
Erscheinungsdatum: 19.10.2021
Gewicht: 0,924 kg
Artikel-ID: 120804813
Warnhinweis